Home
NewsNewsTechnology-Enabled Cryostorage is transforming fertility storage as Reprotech and TMRW combine expertise in digital specimen management and biorepository services. The partnership enhances scalability, safety, and efficiency while supporting clinics with advanced solutions. This strategic move positions the combined company to lead innovation and meet growing global demand in cryostorage services.
Reprotech and TMRW Life Sciences, on 2 April 2026, announced a strategic business combination, bringing together two leaders in fertility storage and technology to create the industry's most comprehensive, Technology-Enabled Cryostorage company for the management and cryostorage of frozen eggs, embryos, and sperm. The combined business will operate under the Reprotech banner, which will now feature the TMRW, Matcher, and Cryologix brands.
Louis Villalba, current Chief Executive Officer of TMRW Life Sciences, will serve as Chief Executive Officer of the combined organisation. Brad Senstra, current Chief Executive Officer of Reprotech, will serve as Chief Operating Officer.
Reprotech brings more than 35 years of leadership in long-term cryostorage, a national network of offsite biorepositories, and established digital witnessing and billing platforms, including Matcher and Cryologix. TMRW contributes its Digital Specimen Management platform, advanced automated and manual storage solutions, and commercial partnerships with leading fertility networks — creating a complete digital solution for the tracking, management, and storage of frozen eggs, embryos, and sperm.
Together, the combined organization will safeguard more than one million fertility specimens, partner with approximately 75% of fertility centers nationwide, support more than 50% of U.S. patient cycles, and operate eight offsite storage facilities.
As the fertility industry continues shifting from fresh to frozen cycles, clinics are managing cryostorage volumes far beyond what much of their original infrastructure was designed to support. This trend is increasing demand for Technology-Enabled Cryostorage solutions that can scale safely, accurately, and efficiently. With complementary strengths across technology, operations, and clinical partnerships, the combined organization is well positioned to support the evolving needs of fertility clinics and patients across the United States, with the opportunity to expand internationally over time.
"There is clear industrial logic in bringing Reprotech and TMRW together," said Luis A. Fernandez, Chairman of the Board of Reprotech. "We are building a company designed to meet the evolving demands of the fertility industry by combining state of the art infrastructure, trusted service, and next-generation technology. Following our investment in IMT Matcher and now with TMRW's Digital Specimen Management platform, we are creating a fully technology-enabled cryostorage offering that can meet clinics where they are today while helping define where the industry is going tomorrow."
The combined organization supports a broad range of fertility clinics, health systems, and patient populations nationwide. Reprotech partners with leading university and hospital-based fertility centers, fertility preservation centers, and many independent fertility practices, while TMRW works with some of the largest fertility networks in the country. The business combination strengthens the combined company's national reach and expands its ability to provide clinics and patients with a unified, flexible solution across both onsite and offsite storage environments.
"At TMRW, our mission has always been to safeguard life's most precious cells and advance the standard of care," said Louis Villalba, incoming Chief Executive Officer of the combined organisation. "By joining forces with Reprotech, we have the opportunity to bring together trusted infrastructure, national scale, and digital innovation in a way that is truly differentiated in the fertility market. I'm excited to lead this next chapter and help build the future of fertility cryostorage."
Throughout the integration process, clinic partners and patients can expect continuity of care, clear communication, expanded digital capabilities, and continued investment in safety, service, and innovation. With a shared commitment to patient safety, regulatory excellence, and continuous innovation, the combined organization is poised to set a new standard for Technology-Enabled Cryostorage.
"With the combined resources of Reprotech and TMRW, we are now able to accelerate the technology and products we offer our partners," said Brad Senstra, Chief Operating Officer of the combined company. "We are moving forward with a truly talented team that will make specimen management safer, streamlined, and more cost-effective for fertility clinics and their patients."
India's Central Drugs Standard Control Organisation has overhauled CDSCO IVF reagent sale norms, directing that all ART media, culture solutions, and reagents be supplied exclusively to clinics registered under the ART (Regulation) Act and Surrogacy (Regulation) Act. The move targets a growing unlicensed supply chain feeding an estimated 40–50% of India's 2,000-plus IVF centres.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
CSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
